AstraZeneca has announced further investment at its Irish plants in Blanchardstown and Athlone.
The company’s rare disease group, Alexion, is building a new manufacturing science and technology lab in Blanchardstown to allow the unit scale up its biologics drug manufacturing in Ireland. It is also installing new manufacturing equipment and temperature controlled warehousing at both sites to boost production here.
The €65 million investment follows a €341 million investment announced last year for the Blanchardstown facility on a new manufacturing unit on the site.
Alexion chief executive Marc Dunoyer said Ireland was “an increasingly critical global hub for AstraZeneca operations” and the new investments would allow “for new capabilities for AstraZeneca in Ireland”.
I’m looking forward to making it into the 15% of people with cystic fibrosis over the age of 40
‘Pope Francis changed the guardrails of Catholicism’: Vatican visitors reflect on pontiff’s legacy
Chief medical officer Mary Horgan: ‘People often forget how bad infections were; our memories sometimes are short’
Londoners and tourists mourn Pope Francis amid Catholicism’s unexpected renaissance in Britain
IDA Ireland chief executive Martin Shanahan said Ireland’s ambition was to be at the forefront of driving the future of biopharma.
“Today’s announcement to continue to increase Alexion capabilities in Ireland further demonstrates the company’s commitment to the rich life-science ecosystem Ireland has to offer,” he said.